Current Cardiology Reports

, Volume 7, Issue 3, pp 155–158 | Cite as

Clinical trials report

  • Ileana L. Piña


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547–1552.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohn JN, Ziesche S, Smith R, et al.: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: VHeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997, 96:856–863.PubMedGoogle Scholar
  4. 4.
    Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283:1295–1302.PubMedCrossRefGoogle Scholar
  5. 5.
    Packer M, Fowler MB, Roecker EB, et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194–2199.PubMedCrossRefGoogle Scholar
  6. 6.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar
  7. 7.
    Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429–1435.Google Scholar
  8. 8.
    Bloche MG: Race-based therapeutics. N Engl J Med 2004, 351:2035–2037.PubMedCrossRefGoogle Scholar
  9. 9.
    Hegele RA: Angiotensin-converting enzyme (ACE) inhibition in the secondary prevention of vascular disease: the Heart Outcomes Prevention Evaluation (HOPE) Trial and its substudies. Curr Atheroscler Rep 2000, 2:361–362.PubMedGoogle Scholar
  10. 10.
    Kwaku M, Burman KD, Becker KL, Mannan M: The EUROPA trial. Lancet 2003, 362:1935–1937.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Ileana L. Piña

There are no affiliations available

Personalised recommendations